PD and PK parameters from all subjects from the AB023 phase 2 clinical trial. Two cohorts were administered a single dose of AB023 (cohort 1, 0.25 mg/kg [n = 8, blue circles]; cohort 2, 0.5 mg/kg [n = 8, light green circles]) or placebo (all placebo-dosed subjects from both cohorts are grouped together [n = 8, red circles]). (A) aPTT for all groups from study day 1 predose (represented as 0 hours on the x-axis) until the end of the trial in hours. Arrowheads show study days where hemodialysis took place. (B) The aPTT data from panel A are expanded to show the first 24 hours postdose on study day 1 so that the data from the early postdose time points can be more clearly seen. (C) PT time from all subjects predose (study days −7, −5, and −3) and postdose (study days 1, 3, 5, and 12). There was no statistical difference in PT found in any cohort compared with placebo. (D) Mean AB023 plasma concentrations after a single IV dose. Plasma concentration of AB023 from both cohorts after a single injection of AB023 (0.25 mg/kg, blue circles; 0.5 mg/kg, light green circles; n = 8 for each dose level). Data represent mean ± SEM.